Boston Common Asset Management LLC held its position in GlaxoSmithKline PLC (NYSE:GSK) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,445 shares of the pharmaceutical company’s stock at the close of the 2nd quarter. Boston Common Asset Management LLC’s holdings in GlaxoSmithKline PLC were worth $450,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Russell Investments Group Ltd. acquired a new position in shares of GlaxoSmithKline PLC during the 1st quarter worth approximately $578,000. Assetmark Inc. grew its position in shares of GlaxoSmithKline PLC by 1.7% in the first quarter. Assetmark Inc. now owns 180,579 shares of the pharmaceutical company’s stock valued at $7,613,000 after purchasing an additional 3,012 shares in the last quarter. Lockheed Martin Investment Management Co. purchased a new stake in shares of GlaxoSmithKline PLC in the first quarter valued at approximately $6,067,000. Rational Advisors LLC purchased a new stake in shares of GlaxoSmithKline PLC in the first quarter valued at approximately $772,000. Finally, Nicholas Hoffman & Company LLC. grew its position in shares of GlaxoSmithKline PLC by 27.4% in the first quarter. Nicholas Hoffman & Company LLC. now owns 30,611 shares of the pharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 6,583 shares in the last quarter. Institutional investors own 9.28% of the company’s stock.

Several research firms recently commented on GSK. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, September 21st. Morgan Stanley lowered GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. Argus reissued a “buy” rating and set a $50.00 price objective on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. BidaskClub upgraded GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Finally, TheStreet cut GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and a consensus target price of $44.67.

GlaxoSmithKline PLC (NYSE:GSK) traded up 0.22% on Tuesday, reaching $41.00. 1,354,265 shares of the company’s stock were exchanged. The company has a market capitalization of $100.20 billion, a PE ratio of 39.73 and a beta of 1.03. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.54. The company has a 50 day moving average price of $39.88 and a 200-day moving average price of $41.67.

GlaxoSmithKline PLC (NYSE:GSK) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The firm had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. On average, equities research analysts anticipate that GlaxoSmithKline PLC will post $2.87 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be paid a $0.491 dividend. This represents a $1.96 dividend on an annualized basis and a yield of 4.80%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 197.00%.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-holdings-held-by-boston-common-asset-management-llc/1605504.html.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.